Plasma metabolomic profiling of patients with acute coronary syndrome treated with potent platelet inhibitors

Read full text Summarise with VIRAT
Authors: Jovan Rogozarski, Gloria M. Gager, Karin Preindl, Zofia Wicik, Ceren Eyileten, Christof Skos, Christopher Gerner, Al Medina Dizdarevic, Marek A Postula, Samuel M. Meier, Jolanta Maria Siller-Matula
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Ticagrelor and prasugrel are key components in the treatment of patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI). However, both antiplatelet agents exhibit pleiotropic actions, leading to several side effects. In previous trials, ticagrelor demonstrated the induction of dyspnea symptoms in patients. Purpose The objective of this study was to assess novel metabolomic indicators associated with the effects of ticagrelor and prasugrel using targeted metabolomic tools. Methods EDTA plasma samples from 207 consecutive ACS patients treated with either prasugrel (n = 106) or ticagrelor (n = 101) were analyzed using a targeted assay for up to 631 metabolites. Results Several metabolites were significantly (p < 0.05) different between the treatment groups. Among these, DHEAS and 3-Met-His had most significant changes (p = 0.0004, FC = -1.66 and p = 0.0024, FC = 1.75, respectively). After stratification for key risk factors, lysoPC a C17:0, 3-Met-His, and DHEAS remained significantly altered. In subgroup analysis, patients with diabetes showed distinct metabolic patterns, including increased TMAO and choline and decreased GUDCA, compared to non-diabetics. Differences were also observed in hexoses, Met-SO, and TCDCA levels. Conclusion A novel hypothesis regarding the pleiotropic actions of ticagrelor suggests that dyspnea may involve low levels of DHEAS. Additionally, decreased methionine and methionine sulfoxide levels may reflect reduced oxidative stress. Diabetic patients exhibited a metabolic shift and altered gut microbiome related metabolites, such as TMAO, contributing to a more ischemic profile.For image description, please refer to the figure legend and surrounding text.

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Metabolomics and Mass Spectrometry Studies Blood Coagulation and Thrombosis Mechanisms

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Publication date
1 March 2026
Language
EN